# üî¨ Inebilizumab Path Analysis Report

*Generated: 2025-12-07 14:00:25*

## 1. Drug Profile

| Property | Value |
|----------|-------|
| **Drug ID** | DB12530 |
| **Drug Name** | Inebilizumab |
| **Type** | drug |

## 2. Path Statistics

| Metric | Value |
|--------|-------|
| **Total Paths** | 100 |
| **Unique Diseases** | 80 |
| **Mean Attention** | 0.6062 |
| **Std Attention** | 0.0457 |
| **Min Attention** | 0.4768 |
| **Max Attention** | 0.7496 |

### Paths by Hop Count

| Hops | Count |
|------|-------|
| 2 | 400 |
| 3 | 400 |
| 4 | 400 |
| 5 | 400 |

## 3. Path Type Summary

| Path Type | Count | Description |
|-----------|-------|-------------|
| Drug Similarity | 100 | Paths through similar drugs |
| Protein Target | 0 | Paths through protein targets |
| Pathway | 0 | Paths through biological pathways |
| Biological Process | 0 | Paths through biological processes |
| Other | 0 | Other connection types |

### Key Similar Drugs

| Similar Drug | Max Attention | # Diseases |
|--------------|---------------|------------|
| Obinutuzumab | 0.7771 | 2 |
| Conjugated estrogens | 0.7561 | 1 |
| Mestranol | 0.7382 | 39 |
| Chlorotrianisene | 0.7278 | 50 |
| Dasatinib | 0.7083 | 8 |

## 4. Top 20 Paths (by Combined Score)

### Path #1: psychologic dyspareunia

**Path:**
```
[Inebilizumab] --(0.756)--> [Conjugated estrogens] --(0.554)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6552 |
| Combined Score | 0.4633 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Conjugated estrogens, which is associated with psychologic dyspareunia. This suggests shared therapeutic mechanisms.

---

### Path #2: obsolete susceptibility to ischemic stroke

**Path:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.539)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6384 |
| Combined Score | 0.4515 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Mestranol, which is associated with obsolete susceptibility to ischemic stroke. This suggests shared therapeutic mechanisms.

---

### Path #3: neurotic disorder

**Path:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.538)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6383 |
| Combined Score | 0.4514 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Mestranol, which is associated with neurotic disorder. This suggests shared therapeutic mechanisms.

---

### Path #4: cervical carcinosarcoma

**Path:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.538)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6383 |
| Combined Score | 0.4513 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Mestranol, which is associated with cervical carcinosarcoma. This suggests shared therapeutic mechanisms.

---

### Path #5: migraine with or without aura, susceptibility to

**Path:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.538)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6380 |
| Combined Score | 0.4511 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Mestranol, which is associated with migraine with or without aura, susceptibility to. This suggests shared therapeutic mechanisms.

---

### Path #6: cerebral infarction

**Path:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.537)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6378 |
| Combined Score | 0.4510 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Mestranol, which is associated with cerebral infarction. This suggests shared therapeutic mechanisms.

---

### Path #7: biliary tract disease

**Path:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.537)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6374 |
| Combined Score | 0.4507 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Mestranol, which is associated with biliary tract disease. This suggests shared therapeutic mechanisms.

---

### Path #8: obstructive jaundice

**Path:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.536)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6369 |
| Combined Score | 0.4504 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Mestranol, which is associated with obstructive jaundice. This suggests shared therapeutic mechanisms.

---

### Path #9: endometrium neoplasm

**Path:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.535)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6366 |
| Combined Score | 0.4502 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Mestranol, which is associated with endometrium neoplasm. This suggests shared therapeutic mechanisms.

---

### Path #10: stroke disorder

**Path:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.535)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6366 |
| Combined Score | 0.4502 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Mestranol, which is associated with stroke disorder. This suggests shared therapeutic mechanisms.

---

### Path #11: coronary artery disease

**Path:**
```
[Inebilizumab] --(0.738)--> [Mestranol] --(0.533)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6359 |
| Combined Score | 0.4496 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Mestranol, which is associated with coronary artery disease. This suggests shared therapeutic mechanisms.

---

### Path #12: ovarian carcinosarcoma

**Path:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.540)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6341 |
| Combined Score | 0.4483 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Chlorotrianisene, which is associated with ovarian carcinosarcoma. This suggests shared therapeutic mechanisms.

---

### Path #13: uterine corpus leiomyoma

**Path:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.538)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6330 |
| Combined Score | 0.4476 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Chlorotrianisene, which is associated with uterine corpus leiomyoma. This suggests shared therapeutic mechanisms.

---

### Path #14: maligant granulosa cell tumor of ovary

**Path:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.537)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6325 |
| Combined Score | 0.4473 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Chlorotrianisene, which is associated with maligant granulosa cell tumor of ovary. This suggests shared therapeutic mechanisms.

---

### Path #15: cerebral infarction

**Path:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.537)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6323 |
| Combined Score | 0.4471 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Chlorotrianisene, which is associated with cerebral infarction. This suggests shared therapeutic mechanisms.

---

### Path #16: intrinsic asthma

**Path:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.536)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6317 |
| Combined Score | 0.4467 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Chlorotrianisene, which is associated with intrinsic asthma. This suggests shared therapeutic mechanisms.

---

### Path #17: migraine with or without aura, susceptibility to

**Path:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.535)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6314 |
| Combined Score | 0.4465 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Chlorotrianisene, which is associated with migraine with or without aura, susceptibility to. This suggests shared therapeutic mechanisms.

---

### Path #18: endometrium neoplasm

**Path:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.535)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6315 |
| Combined Score | 0.4465 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Chlorotrianisene, which is associated with endometrium neoplasm. This suggests shared therapeutic mechanisms.

---

### Path #19: obsolete susceptibility to ischemic stroke

**Path:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.534)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6311 |
| Combined Score | 0.4463 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Chlorotrianisene, which is associated with obsolete susceptibility to ischemic stroke. This suggests shared therapeutic mechanisms.

---

### Path #20: ovarian small cell carcinoma

**Path:**
```
[Inebilizumab] --(0.728)--> [Chlorotrianisene] --(0.534)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.6310 |
| Combined Score | 0.4462 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê High |

**Node Types:** `drug` ‚Üí `drug` ‚Üí `disease`

**Interpretation:**

**Drug similarity path**: Inebilizumab is similar to Chlorotrianisene, which is associated with ovarian small cell carcinoma. This suggests shared therapeutic mechanisms.

---

## 5. Interpretation Guidelines

### Attention Score Scale

| Score Range | Confidence | Interpretation |
|-------------|------------|----------------|
| ‚â• 0.70 | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High | Strong biological relationship |
| 0.60 - 0.70 | ‚≠ê‚≠ê‚≠ê‚≠ê High | Good evidence for connection |
| 0.50 - 0.60 | ‚≠ê‚≠ê‚≠ê Medium | Moderate support |
| 0.40 - 0.50 | ‚≠ê‚≠ê Low | Weak connection |
| < 0.40 | ‚≠ê Very Low | Speculative |

### How to Use This Report

1. **Prioritize high-scoring paths**: Focus on paths with combined scores > 0.45
2. **Validate intermediate nodes**: Cross-reference proteins/drugs with literature
3. **Consider path length**: Shorter paths (2-3 hops) are generally more reliable
4. **Check for known associations**: Some paths may represent known indications

---

*Report generated by TxGNN Path Analysis Pipeline*